Abstract:
As part of a comprehensive and effective response to HIV/AIDS, the process of securing and sustaining the
continuity of pharmaceutical supplies in rapidly growing programs requires considerable financial and human
resources, strong supply chain management, and close coordination. The Federal Ministry of Health, Ethiopian
Pharmaceuticals Supply Agency (EPSA), Federal HIV/AIDS Prevention and Control Office (FHAPCO),
Ethiopian Public Health Institute (EPHI), and partners consider the routine and comprehensive quantification of
HIV/AIDS pharmaceuticals to be a critical step in implementing an effective program. To quantify health
commodity demands, stakeholders considered several current developments in the HIV/AIDS prevention and
control program:Revision of the national guidelines for comprehensive HIV prevention, care, and
treatment; introduction of dolutegravir based regimen; NVP based regimen shift; optimization of
pediatrics regimen; introduction of third-line treatment; change in test protocol; introduction of new
laboratory testing equipment and pediatrics accelerated plan. The objective of the workshop was to review
currently assessed data on program performance and reach consensus on the data and other key assumptions
required to forecast HIV/AIDS commodity needs from July 2019 to June 2021. The scope includes:ARVs for
all pediatric and adult clients; medicines for prevention of mother-to-child transmission (PMTCT);
medicines for pre-exposure prophylaxis (PrEP); medicines for prevention and treatment of
opportunistic infection; HIV diagnostic rapid test kits; Early infant diagnosis (EID) pharmaceuticals;
Viral load (VL) monitoring and other ART monitoring laboratory pharmaceuticals; medicines for
treating sexually transmitted infections (STIs) and condoms for HIV prevention. Forecast results are
shown in detail in different sections of this document. Costs of the different subcategories of products are
summarized in Table1. Costs include product and procurement and supply management-related costs.
